Somatodendritic action of pindolol to attenuate the paroxetine-induced decrease in serotonin release from the rat...

Area of Science:

• Neuropharmacology
• Neuroscience
• Biochemistry

Background:

• Selective serotonin reuptake inhibitors (SSRIs) like paroxetine are widely used antidepressants.
• The role of presynaptic serotonin (5-HT) autoreceptors in regulating 5-HT release is not fully understood.
• Understanding these mechanisms is crucial for optimizing antidepressant therapy.

Purpose of the Study:

• To investigate the role of raphe and presynaptic serotonin (5-HT) autoreceptors in paroxetine's effect on 5-HT release.
• To examine how pindolol, a 5-HT(1A) receptor antagonist, modulates the hippocampal 5-HT response to paroxetine.
• To elucidate the specific autoreceptor targets involved in regulating 5-HT outflow.

Main Methods:

• Intracerebral microdialysis in anesthetized rats to measure extracellular 5-HT levels in the ventral hippocampus.
• Local infusion of paroxetine and pindolol isomers into the ventral hippocampus and median raphe.
• Systemic administration of paroxetine and pindolol for comparative analysis.

Main Results:

• Systemic paroxetine was less effective than local infusion in increasing extracellular 5-HT, indicating reduced release.
• Systemic paroxetine decreased hippocampal 5-HT release when reuptake was blocked, suggesting reduced neuronal release.
• Pindolol, particularly (-)-pindolol, blocked the paroxetine-induced decrease in 5-HT release, with effects localized to the median raphe.

Conclusions:

• Systemic administration of SSRIs like paroxetine can decrease 5-HT release from neuronal terminals.
• Pindolol preferentially blocks somatodendritic 5-HT(1A) autoreceptors, restoring 5-HT outflow.
• These findings highlight the importance of 5-HT(1A) autoreceptors in regulating serotonin levels during SSRI treatment.